MX2013013931A - Medios y metodos para diagnosticar y tratar esclerosis multiple. - Google Patents

Medios y metodos para diagnosticar y tratar esclerosis multiple.

Info

Publication number
MX2013013931A
MX2013013931A MX2013013931A MX2013013931A MX2013013931A MX 2013013931 A MX2013013931 A MX 2013013931A MX 2013013931 A MX2013013931 A MX 2013013931A MX 2013013931 A MX2013013931 A MX 2013013931A MX 2013013931 A MX2013013931 A MX 2013013931A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
seq
peptide
diagnosing
set forth
Prior art date
Application number
MX2013013931A
Other languages
English (en)
Other versions
MX343630B (es
Inventor
Bernhard Hemmer
Rajneesh Srivastava
Original Assignee
Klinikum Rechts Der Isar Der Tech Universität München
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinikum Rechts Der Isar Der Tech Universität München filed Critical Klinikum Rechts Der Isar Der Tech Universität München
Publication of MX2013013931A publication Critical patent/MX2013013931A/es
Publication of MX343630B publication Critical patent/MX343630B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)

Abstract

La invención se refiere a un péptido que comprende o consiste de al menos 8 residuos de aminoácido de la secuencia establecida en SEC ID NO: 3, siempre que dicho péptido no consista de la secuencia establecida en SEC ID NO: 3, o un peptidomimético correspondiente, en donde dicho péptido o peptidomimético se une a un anticuerpo anti-KIR4.1 comprendido en una muestra de un paciente, dicho paciente teniendo esclerosis múltiple o una predisposición para la misma, en donde preferiblemente (i) dichos al menos 8 residuos de aminoácido son una sub-secuencia de un dominio extracelular de KIR4.1, dicho dominio extracelular consistiendo de la secuencia establecida en SEC ID NO: 1 o 2; o (ii) dicho péptido comprende o consiste de la secuencia de SEC ID NO: 1 o 2. La presente invención además se refiere a un método para diagnosticar esclerosis múltiple o una predisposición para esclerosis múltiple en un sujeto, el método comprende determinar la presencia de un anticuerpo anti-KIR4.1 en una muestra obtenida de dicho sujeto, en donde la presencia de un anticuerpo anti-KIR4.1 en dicha muestra es indicativa de esclerosis múltiple o una predisposición para esclerosis múltiple. También se proporcionan medios novedosos y métodos para la terapia de esclerosis múltiple.
MX2013013931A 2011-05-30 2012-05-23 Medios y metodos para diagnosticar y tratar esclerosis multiple. MX343630B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11004423A EP2530088A1 (en) 2011-05-30 2011-05-30 Means and methods for diagnosing and treating multiple sclerosis
PCT/EP2012/059622 WO2012163765A1 (en) 2011-05-30 2012-05-23 Means and methods for diagnosing and treating multiple sclerosis

Publications (2)

Publication Number Publication Date
MX2013013931A true MX2013013931A (es) 2014-04-25
MX343630B MX343630B (es) 2016-11-14

Family

ID=45418833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013931A MX343630B (es) 2011-05-30 2012-05-23 Medios y metodos para diagnosticar y tratar esclerosis multiple.

Country Status (13)

Country Link
US (2) US9297809B2 (es)
EP (2) EP2530088A1 (es)
JP (2) JP6316746B2 (es)
KR (1) KR102021107B1 (es)
CN (1) CN103687871B (es)
AU (1) AU2012264943B2 (es)
BR (1) BR112013030473A2 (es)
CA (1) CA2832391C (es)
DK (1) DK2714729T3 (es)
IL (1) IL229704A (es)
MX (1) MX343630B (es)
RU (1) RU2601298C2 (es)
WO (1) WO2012163765A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015254596B2 (en) * 2014-04-30 2020-10-22 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Diagnosis of multiple sclerosis
WO2017062682A2 (en) * 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
RU2648215C1 (ru) * 2017-03-01 2018-03-22 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ дифференциальной диагностики органических поражений цнс у детей в остром периоде
CN108853505B (zh) * 2017-05-09 2022-02-25 浙江大学 钾离子通道抑制剂治疗抑郁症的用途和药物组合物
KR102282341B1 (ko) * 2018-09-12 2021-07-27 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
RU2741929C1 (ru) * 2020-06-19 2021-01-29 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционный болезней Федерального медико-биологического агентства" Способ прогнозирования риска развития энцефалопатии критических состояний у детей с инфекционными заболеваниями
WO2023056387A1 (en) * 2021-09-29 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Diagnosing multiple sclerosis (ms)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7262290B2 (en) * 2000-08-28 2007-08-28 Trustees Of The University Of Pennsylvania Diagnostic markers for multiple epilepsy phenotypes
JP2003079270A (ja) * 2001-09-10 2003-03-18 Japan Science & Technology Corp ミエリン発達障害モデル非ヒト動物
RU2214839C2 (ru) * 2001-10-26 2003-10-27 Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН Способ лечения рассеянного склероза
RU2369874C2 (ru) * 2002-08-02 2009-10-10 Гликоминдс Лтд. Способ диагностики рассеянного склероза
US9353190B2 (en) * 2006-03-30 2016-05-31 The Board Of Trustees Of The Leland Stanford Junio Compositions, systems and methods for the diagnosis, prevention and treatment of disorders associated with azetidine-2-carboxylic acid
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
EP2488196B1 (en) 2009-10-12 2015-12-16 LIFEBio Laboratories LLC Composition for treatment of multiple sclerosis
US9732138B2 (en) * 2010-02-09 2017-08-15 Yale University Loss of function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
WO2012094394A2 (en) * 2011-01-04 2012-07-12 Yale University Methods and compositions for assessing and treating adrenal diseases and disorders

Also Published As

Publication number Publication date
JP2018058852A (ja) 2018-04-12
JP6316746B2 (ja) 2018-04-25
CA2832391A1 (en) 2012-12-06
US20160161482A1 (en) 2016-06-09
US9297809B2 (en) 2016-03-29
BR112013030473A2 (pt) 2016-11-29
RU2601298C2 (ru) 2016-10-27
CN103687871B (zh) 2016-03-02
WO2012163765A1 (en) 2012-12-06
US9733244B2 (en) 2017-08-15
CN103687871A (zh) 2014-03-26
IL229704A0 (en) 2014-01-30
RU2013158334A (ru) 2015-07-10
CA2832391C (en) 2019-10-29
EP2714729B1 (en) 2020-01-01
MX343630B (es) 2016-11-14
DK2714729T3 (da) 2020-03-16
AU2012264943A1 (en) 2013-10-17
JP2014523869A (ja) 2014-09-18
EP2530088A1 (en) 2012-12-05
EP2714729A1 (en) 2014-04-09
AU2012264943B2 (en) 2016-12-15
NZ615912A (en) 2016-05-27
US20140080156A1 (en) 2014-03-20
IL229704A (en) 2017-12-31
KR102021107B1 (ko) 2019-09-11
NZ717188A (en) 2017-08-25
KR20140043892A (ko) 2014-04-11

Similar Documents

Publication Publication Date Title
MX343630B (es) Medios y metodos para diagnosticar y tratar esclerosis multiple.
WO2012160563A3 (en) Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
JO3242B1 (ar) طرق علاج داء السكري بمستضادات dll4
EA201001874A1 (ru) Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
MX2015014608A (es) Novedosas moleculas de union biespecifica con actividad antitumoral.
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
MX337991B (es) Metodo para detectar cancer.
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
NZ601591A (en) Methods for treating pancreatic cancer
WO2011063003A3 (en) Peptides and methods for the detection of lyme disease antibodies
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
EA201100072A1 (ru) Новые композиции и способы
EA201390820A1 (ru) Слитый белок против рака
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
MX2015000686A (es) Metodo para detectar cancer.
EA201270701A1 (ru) Ингибирующие металлопротеины антитела
RU2016141144A (ru) Способ супрессии злокачественной опухоли посредством ингибирования тмсс3
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
IN2014CN01466A (es)
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
NZ598035A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
FG Grant or registration